European Society for Impotence Research--third meeting. 30 January-2 February 2000, Barcelona, Spain.
The role of sildenafil (Viagra; Pfizer Inc) in a variety of indications, including spinal cord injury following prostatectomy, was presented. Results obtained by comparing different therapies were also presented. The role of sildenafil in long-term users of intracavernous and intra-urethral therapy was presented by at least two groups with interesting results. Conversely, a presentation on the role of intracavernosal therapy in patients who had failed to respond to sildenafil revealed thought provoking-findings. The anticipation by delegates of an opportunity to preview new therapy was also satisfied, at least in part, with presentations on Invicorp (Senetek plc), sublingual apomorphine (TAP Pharmaceuticals Inc), BAY-38-9456 (Bayer Yakuhin Ltd), and a yohimbine/arginine combination. MUSE therapy (VIVUS Inc) was also revisited. The various presentations on the treatment of erectile dysfunction revealed a trend towards a more practical approach.
Adeniyi
A
A
Institute of Urology and Nephrology, St Peter's/Middlesex Hospital, Mortimer Street, London, W1N 8AA, UK. a.adeniyi@ucl.ac.uk